News
IMTX
9.45
+0.96%
0.09
Immatics Raises $161 Million in Completed Equity Offering to Advance PRAME Cancer Programs
TipRanks · 3d ago
Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma
Seeking Alpha · 4d ago
Immatics price target lowered to $17 from $18 at Jefferies
TipRanks · 4d ago
Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday
Benzinga · 4d ago
Immatics Announces $150 Million Underwritten Offering; Stock Up
NASDAQ · 4d ago
Immatics launches $150M securities offering
Seeking Alpha · 4d ago
Immatics announces $150M offering of common stock priced at $8.69 per share
TipRanks · 4d ago
Immatics Announces $150M Underwritten Offering Of Ordinary Shares And Pre-Funded Warrants
Benzinga · 4d ago
Weekly Report: what happened at IMTX last week (0817-0821)?
Weekly Report · 5d ago
Iovance Biotherapeutics: Breakout Quarter, Catalysts Ahead, And Competitor Updates
Seeking Alpha · 08/20 15:03
Analysts Offer Insights on Healthcare Companies: AEON Biopharma (AEON), BioMarin Pharmaceutical (BMRN) and Immatics (IMTX)
TipRanks · 08/19 13:40
Analysts’ Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Immatics (IMTX)
TipRanks · 08/19 08:50
Immatics Advances Anzu-cel Phase 3 Program; Reports Q2 Revenue Growth
NASDAQ · 08/18 14:54
Morning Movers: Klarna sinks following second quarter results, trimmed guidance
TipRanks · 08/18 13:01
Immatics Q2 EPS $(0.53) Misses $(0.43) Estimate, Sales $10.630M Miss $14.590M Estimate
Benzinga · 08/18 11:33
Immatics Posts Interim Q2 2026 Results and Updates Investor Materials
TipRanks · 08/18 11:27
Immatics reports Q2 EPS (46c), consensus (48c)
TipRanks · 08/18 11:06
Immatics GAAP EPS of -€0.46, revenue of €9.14M
Seeking Alpha · 08/18 11:04
Immatics: Q2 Earnings Snapshot
Barchart · 08/18 06:06
Weekly Report: what happened at IMTX last week (0810-0814)?
Weekly Report · 08/17 09:51
More
Webull provides a variety of real-time IMTX stock news. You can receive the latest news about Immatics N.V through multiple platforms. This information may help you make smarter investment decisions.
About IMTX
Immatics N.V. is a clinical-stage biopharmaceutical company. The Company is primarily engaged in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.PRAME is a target expressed approximately 50 cancers. Its PRAME franchise includes approximately three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy. The Company has approximately two technology platforms for target and T Cell Receptor (TCR) discovery.